Ceftazidime stability and pyridine toxicity during continuous i.v. infusion

Area of Science:

• Pharmacology
• Infectious Diseases
• Clinical Pharmacy

Background:

• Ceftazidime is an antibiotic commonly administered via continuous intravenous (IV) infusion.
• Concerns exist regarding the stability of ceftazidime and potential toxicity from pyridine, a degradation product.
• Recent guidance suggests more frequent changes of infusion devices, impacting outpatient practicality.

Purpose of the Study:

• To review the literature on ceftazidime stability and pyridine toxicity.
• To evaluate the safety and practicality of continuous IV infusion in the outpatient setting.
• To determine optimal conditions for minimizing ceftazidime degradation and pyridine formation.

Main Methods:

• Literature review of ceftazidime stability, degradation products, and clinical use.
• Analysis of factors influencing ceftazidime degradation: temperature, concentration, and solvent.
• Pharmacokinetic/pharmacodynamic considerations for continuous IV infusion.

Main Results:

• Ceftazidime degradation and pyridine formation are dependent on temperature, concentration, and solvent.
• Optimal conditions include low dose, ≤3% concentration, 0.9% sodium chloride diluent, and 15-25°C temperature.
• These conditions minimize pyridine formation over 24 hours, preventing toxicity.

Conclusions:

• Continuous IV infusion is the ideal administration route for ceftazidime in outpatients.
• Controlling infusion solution concentration and temperature allows for safe and effective once-daily device changes.
• This approach avoids more frequent device changes, reducing infection risk and improving home care practicality.